Cosmo Pharmaceuticals N.V (C43) — Financial Flexibility Index
Cosmo Pharmaceuticals N.V (C43) has a Financial Flexibility Index of 0.02x as of June 2022. Free cash flow of €7.39 Million (operating CF €6.28 Million minus capex €1.11 Million) represents 0% of total liabilities (€296.03 Million). Check strategic asset allocation of Cosmo Pharmaceuticals N.V to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Cosmo Pharmaceuticals N.V Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Cosmo Pharmaceuticals N.V across 10 annual periods. See Cosmo Pharmaceuticals N.V (C43) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Cosmo Pharmaceuticals N.V (2016–2025)
Year-by-year free cash flow to debt coverage for Cosmo Pharmaceuticals N.V. For the full company profile including market capitalisation, see Cosmo Pharmaceuticals N.V market capitalisation.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.06x | €-7.02 Million | €-12.48 Million | €123.46 Million | ▼ -104.8% |
| 2024 | 1.19x | €168.06 Million | €162.41 Million | €141.68 Million | ▲ +196.8% |
| 2023 | 0.40x | €48.93 Million | €33.62 Million | €122.42 Million | ▲ +191.7% |
| 2022 | 0.14x | €40.54 Million | €33.23 Million | €295.80 Million | ▲ +121.8% |
| 2021 | 0.06x | €18.10 Million | €12.61 Million | €292.88 Million | ▼ -29.2% |
| 2020 | 0.09x | €17.11 Million | €12.98 Million | €196.04 Million | ▲ +200.6% |
| 2019 | -0.09x | €-16.60 Million | €-18.85 Million | €191.43 Million | ▼ -89.7% |
| 2018 | -0.05x | €-8.27 Million | €-10.16 Million | €180.83 Million | ▼ -144.5% |
| 2017 | 0.10x | €2.86 Million | €-9.43 Million | €27.86 Million | ▼ -92.9% |
| 2016 | 1.44x | €40.12 Million | €21.69 Million | €27.92 Million | — |